Nevanimibe is an investigational drug being studied for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome.
Nevanimibe in Congenital Adrenal Hyperplasia (CAH):
Millendo initiated a Phase 2b trial of nevanimibe in CAH in July 2018. For more information please visit https://clinicaltrials.gov/ct2/show/NCT03669549?term=millendo&cond=congenital
Nevanimibe in Cushing’s syndrome:
A Phase 2 trial of nevanimibe for the treatment of patients with Cushing’s syndrome is ongoing. For more information please visit https://clinicaltrials.gov/ct2/show/NCT03053271